Thrombocytopenia Ppt lecture notes 600 free access articles

Thrombocytopenia
http://www.medicine.wisc.edu/

Heparin Induced Thrombocytopenia
Michael E. Lazarus, MD
http://medres.med.ucla.edu/

Neonatal Thrombocytopenia
Archana Jayaram
http://navigator.medschool.pitt.edu/

Hematology
Joyce Smith RN BSN
http://legacy.owensboro.kctcs.edu/

Thrombocytopenia
http://www.stritch.luc.edu/

Hemorrhagic Diseases
Arthur S. Schneider, M.D
http://cmspath.edu/

Hematologic Manifestations of Lupus
Nicole Cullen
https://medicine.med.unc.edu/

Approach to Thrombocytopenia
Selim Krim, MD
http://test.ttuhsc.edu/

Evaluation of the Bleeding Patient
http://www.medicine.wisc.edu

Hematology Board Review
Stephan Moll
http://www.med.unc.edu/

Hemolytic-Uremic Syndrome
Palak Parikh
http://www.med.unc.edu/

Thrombotic Thrombocytopenic Purpura
Serena Ezzeddine
http://www.med.unc.edu/

TTP in HIV A New Entity?
Kristine Scruggs, MD
http://www.med.unc.edu/

Microangiopathic hemolytic anemia/thrombocytopenia
http://www.medicine.wisc.edu/

Hematologic System
Amanda Hawkins
http://www.georgiahealth.edu/

Indications for Platelet Transfusion
Laura Cooling MD, MS
http://www.med.umich.edu

HIV-Associated Thrombotic Microangiopathy
Jack Kuritzky
https://medicine.med.unc.edu/

Bleeding Disorders
Jennifer Kloesz, M.D
http://navigator.medschool.pitt.edu/

Bleeding Disorders
Richard A. McPherson, M.D.
http://www.pathology.vcu.edu/

Massive Transfusion And Coagulopathy
Christine Mai, MD
http://www.bu.edu/

600 free access published scholarly articles

1. A Rare Case of Acute Myocardial Infarction due to Coronary Artery Dissection and Heparin-Induced Thrombocytopenia.
2. Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era.
3. Highly Fluctuating Thrombocytopenia Developing in a Patient with Immune Thrombocytopenia (ITP) while Administering Romiplostim.
4. Foetal-neonatal alloimmune thrombocytopenia due to anti-HPA-2b antibodies present in the serum of a mother initially mistyped as HPA-1a negative.
5. Rituximab for children with immune thrombocytopenia: a systematic review.
6. Severe thrombocytopenia in liver transplantation.
7. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases.
8. Fatal thrombocytopenia: A rare case with possible explanation.
9. Fatal thrombocytopenia associated with intracardiac mass.
10. Severe Fever with thrombocytopenia syndrome virus, shandong province, china.
11. Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
12. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim.
13. Newborn with multifocal lymphangioendotheliomatosis with thrombocytopenia.
14. Pandemic H1N1 influenza with atypical presentation: Encephalopathy and severe thrombocytopenia.
15. Pre-emptive use of bivalirudin for emergent off-pump coronary artery bypass surgery in a suspected case of heparin-induced thrombocytopenia.
16. Severe Thrombocytopenia and Hemorrhagic Diathesis due to Brucellosis.
17. [Role of anti c-mpl antibody in systemic lupus erythematosus with thrombocytopenia].
18. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study.
19. A case report of primary breast angiosarcoma with fatal pulmonary hemorrhage due to thrombocytopenia.
20. Triad of iron deficiency anemia, severe thrombocytopenia and menorrhagia-a case report and literature review.
21. Usefulness of anti-PF4/heparin antibody test for intensive care unit patients with thrombocytopenia.
22. Glucocorticoid-dependent hypoadrenocorticism with thrombocytopenia and neutropenia mimicking sepsis in a Labrador retriever dog.
23. A case of isoniazid-induced thrombocytopenia: recovery with immunoglobulin therapy.
24. [Infectious mononucleosis and severe thrombocytopenia.]
25. A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
26. Patient-reported treatment burden of chronic immune thrombocytopenia therapies.
27. Early post-operative thrombosis of the prosthetic mitral valve in patient with heparin-induced thrombocytopenia.
28. Trends in the Prevalence of Thrombocytopenia among Individuals Infected with Hepatitis C Virus in the United States, 1999-2008.
29. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.
30. Heparin induced thrombocytopenia: case presentation and review.
31. Mycoplasma pneumonia Infection: A Possible Trigger for Immune Thrombocytopenia.
32. A Case of HIV Infection with Thrombocytopenia: Assosiation of HIV, Thrombotic Thrombocytopenic Purpura and Brucellosis.
33. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices.
34. Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia.
35. Xanthogranulomatous pyelonephritis presenting with thrombocytopenia and renal mass.
36. Thrombocytopenia due to rifampicin.
37. A rare case of arterial thrombosis due to heparin-induced thrombocytopenia.
38. [Severe thrombocytopenia on admission to the intensive care unit in patients with multiple organ failure].
39. The wandering spleen: an unusual case of thrombocytopenia.
40. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review.
41. Sporadic case infected by severe fever with thrombocytopenia syndrome bunyavirus in a non-epidemic region of China.
42. Fondaparinux-associated heparin-induced thrombocytopenia.
43. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
44. Persistent thrombocytopenia due to scrub typhus.
45. Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease.
46. [Assessment of fetal well-being in pregnancies complicated by maternal moderate to severe thrombocytopenia].
47. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia.
48. New therapeutic options for immune thrombocytopenia.
49. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
50. Heparin-induced thrombocytopenia screening and management in pediatric patients.
51. Thrombopoietin-receptor agonists for immune thrombocytopenia.
52. Immune thrombocytopenia in children and adults: what's the same, what's different?
53. Severe thrombocytopenia following tirofiban infusion.
54. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus.
55. The development of severe neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies is correlated to maternal ABO genotypes.
56. Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact.
57. Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature.
58. Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia.
59. Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure.
60. Management of acquired thrombophilic disorders in 2011: focus on heparin-induced thrombocytopenia, antiphospholipid syndrome, myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria.
61. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia.
62. Thrombocytopenia and retinopathy of prematurity.
63. [Acute myocardial infarction and chronic leukaemia with significant thrombocytopenia].
64. A case of anemia with schistocytosis, thrombocytopenia, and acute renal failure caused by adenomyosis.
65. [Thrombocytopenia in pregnancy and neonatal outcomes].
66. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia.
67. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.
68. Two patterns of thrombopoietin signaling suggest no coupling between platelet production and thrombopoietin reactivity in thrombocytopenia-absent radii syndrome.
69. Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation).
70. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin.
71. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.
72. Thrombocytopenia in malaria: who cares?
73. Re: Heparin-induced thrombocytopenia - Type 2.
74. A Case of Primary Bone Marrow B-Cell Non Hodgkin's Lymphoma with Severe Thrombocytopenia: Case Report and A Review of the Literature.
75. Thrombocytopenia in cardiac surgery: diagnostic and prognostic importance.
76. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group.
77. [Primary immune thrombocytopenia in a patient with sarcoidosis].
78. Pathway of Toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo.
79. Piracetam-induced immune thrombocytopenia.
80. Rapid identification of thrombocytopenia-associated multiple organ failure using red blood cell parameters and a volume/hemoglobin concentration cytogram.
81. A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
82. Isoniazid causing drug-induced thrombocytopenia.
83. Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach.
84. Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow.
85. [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
86. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.
87. Characteristics and management patterns of patients admitted with Fever and thrombocytopenia to an acute general medical unit in sri lanka.
88. Octreotide-induced thrombocytopenia: a case report.
89. Severe isolated thrombocytopenia after clopidogrel and pentoxifylline therapy: a case report.
90. Heparin-induced thrombocytopenia in a glioblastoma multiforme patient with inferior vena cava filter placement for deep venous thrombosis.
91. A POTEntial new gene for thrombocytopenia.
92. Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients.
93. [The incidence of thrombocytopenia after cardiopulmonary bypass in children with Down syndrome].
94. Heparin-induced thrombocytopenia.
95. Immune thrombocytopenia: no longer 'idiopathic'.
96. Systemic lupus erythematosus presenting as thrombotic thrombocytopenia purpura: how close is close enough?
97. Diffuse large B-cell lymphoma complicated with autoimmune thrombocytopenia.
98. Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia.
99. Resolution of dialyzer membrane-associated thrombocytopenia with use of cellulose triacetate membrane: a case report.
100. Thrombocytopenia in Staphylococcus aureus bacteremia: risk factors and prognostic importance.
101. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP).
102. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
103. The experience of Flebogammadif® in primary immune thrombocytopenia.
104. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro.
105. Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia.
106. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families.
107. Heparin-induced thrombocytopenia in the ICU: an overview.
108. Ranitidine-induced thrombocytopenia: A rare drug reaction.
109. Two cases of valvular thrombosis secondary to heparin-induced thrombocytopenia managed without surgery.
110. Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think.
111. Fever with thrombocytopenia associated with a novel bunyavirus in China.
112. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
113. Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia.
114. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.
115. [What is the prognosis of chronic immune thrombocytopenia?].
116. Severe thrombocytopenia in aged rhesus macaques (Macaca mulatta) infected with simian varicella virus.
117. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
118. Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study.
119. Heparin-induced thrombocytopenia and warfarin-induced skin necrosis: case report.
120. Acute stent thrombosis associated with heparin-induced thrombocytopenia and abciximab-induced profound thrombocytopenia.
121. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.
122. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
123. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.
124. Idiopathic thrombocytopenia and Helicobacter pylori infection: platelet count increase and early eradication therapy.
125. Pathophysiology and therapeutic options in primary immune thrombocytopenia.
126. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia.
127. Utility of ELISA optical density values and clinical scores for the diagnosis of and thrombosis prediction in heparin-induced thrombocytopenia.
128. Thrombocytopenia in pregnancy.
129. Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
130. Immune thrombocytopenia.
131. Thrombocytopenia in the intensive care unit patient.
132. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia.
133. Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma.
134. Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2.
135. Diabetic ketoacidosis preceding thrombocytopenia associated multiple organ failure in a child.
136. The incidence of thrombocytopenia in children with Cornelia de Lange syndrome.
137. Acute Thrombocytopenia, Leucopenia, and Multiorgan Dysfunction: The First Case of SFTS Bunyavirus outside China?
138. Subdural haematoma in pregnancy-induced idiopathic thrombocytopenia: Conservative management.
139. Thrombocytopenia in chronic hepatitis C.
140. Further insights into the causes of thrombocytopenia in chronic hepatitis C.
141. Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.
142. Congenital amegakaryocytic thrombocytopenia: a brief review of the literature.
143. HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia.
144. Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia.
145. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia.
146. Immunoglobulin M antiplatelet autoantibodies from mice immunized with rat platelets induce thrombocytopenia and platelet function impairment.
147. Clinical and radiologic evaluation of cytomegalovirus-induced thrombocytopenia in infants between 1 and 6 months of age.
148. 'Pseudo Wine Glass' Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation.
149. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.
150. Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention.
151. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.
152. A case of levetiracetam-induced thrombocytopenia.
153. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review.
154. Romiplostim or standard of care in patients with immune thrombocytopenia.
155. [Immune thrombocytopenia--pathophysiology and treatment].
156. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?
157. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.
158. Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever?
159. Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.
160. Are there more tricks in the bag for treating thrombocytopenia?
161. Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
162. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.
163. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia.
164. [WASP gene mutation analysis of a family of X-linked thrombocytopenia].
165. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
166. Immune thrombocytopenia in a challenging case of disseminated tuberculosis: a case report and review of the literature.
167. Rifampicin-induced thrombocytopenia.
168. Immature platelet fraction: establishment of a reference interval and diagnostic measure for thrombocytopenia.
169. Iloprost-induced thrombocytopenia: a case proven by rechallenge.
170. A putative role for platelet-derived PPARγ in vascular homeostasis demonstrated by anti-PPARγ induction of bleeding, thrombocytopenia and compensatory megakaryocytopoiesis.
171. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.
172. Argatroban in the management of heparin-induced thrombocytopenia.
173. Heparin induced thrombocytopenia-type 2.
174. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
175. Image in medicine. A case of congenital haemolytic anaemia and thrombocytopenia. Upshaw-Schulman syndrome (congenital thrombotic thrombocytopenic purpura).
176. Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.
177. Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits.
178. Warfarin-induced penile necrosis in a patient with heparin-induced thrombocytopenia.
179. Drug-induced hemolytic anemia and thrombocytopenia associated with alterations of cell membrane lipids and acanthocyte formation.
180. Malaria vivax and Severe Thrombocytopenia in Iran.
181. Heparin-induced thrombocytopenia and cerebral venous thrombosis after low-molecular weight heparin.
182. Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
183. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.
184. A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy.
185. Pyrazinamide induced thrombocytopenia.
186. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.
187. Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation.
188. A case of splenic torsion with progressive anemia and thrombocytopenia.
189. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia.
190. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy.
191. Metastatic cutaneous angiosarcoma complicated with severe thrombocytopenia.
192. eComment: Heparin-induced thrombocytopenia in cardiac surgery.
193. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study.
194. Neonatal thrombocytopenia and megakaryocytopoiesis.
195. [Acquired amegakaryocytic thrombocytopenia after thymectomy in a case of pure red cell aplasia associated with thymoma].
196. Methylprednisolone-induced immune thrombocytopenia.
197. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia.
198. Whole blood viscosity assessment issues III: Association with international normalized ratio and thrombocytopenia.
199. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.
200. Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway.
201. Coronary artery bypass grafting in idiopathic thrombocytopenia: use of thromboelastometry without platelet transfusion.
202. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
203. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.
204. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion.
205. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.
206. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.
207. Serious acute coronary thrombosis associated with heparin-induced thrombocytopenia in off-pump coronary artery bypass grafting.
208. [Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
209. [Autoimmune thrombocytopenia--a therapeutic challenge].
210. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
211. Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves' disease.
212. [Guideline for diagnosis and treatment of immune thrombocytopenia].
213. Cerebral sinus thrombosis and heparin-induced thrombocytopenia in a patient with paroxysmal nocturnal hemoglobinuria.
214. Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE.
215. Thrombocytopenia and splenomegaly: an unusual presentation of congenital hepatic fibrosis.
216. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
217. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
218. HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region.
219. Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.
220. Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine.
221. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
222. Thrombocytopenia Absent Radius Syndrome .
223. Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.
224. Superior vena cava syndrome in a patient with severe thrombocytopenia.
225. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
226. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
227. [Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus].
228. Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.
229. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation.
230. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
231. Budd-Chiari syndrome and heparin-induced thrombocytopenia in polycythemia vera: successful treatment with repeated TIPS and interferon alpha.
232. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database.
233. Differences between newborn and adult mice in their response to immune thrombocytopenia.
234. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
235. Thrombocytopenia and iodinated contrast.
236. Thrombocytopenia and its related factors: a hospital-based, cross-sectional study.
237. Steroid responsive prolonged thrombocytopenia in dengue.
238. A hypothesis that explains the heterogeneity of drug-induced immune thrombocytopenia.
239. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment.
240. Thrombocytopenia, an important interfering factor of antiviral therapy and hepatocellular carcinoma treatment for chronic liver diseases.
241. An outbreak of late-term abortions, premature births, and congenital deformities associated with a bovine viral diarrhea virus 1 subtype b that induces thrombocytopenia.
242. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag.
243. Cerebellar nocardiosis and myopathy from long-term corticosteroids for idiopathic thrombocytopenia.
244. Immune-mediated thrombocytopenia associated with angiostrongylus vasorum infection in a Jack Russell terrier.
245. Profound thrombocytopenia after primary exposure to eptifibatide.
246. Trastuzumab-related thrombocytopenia: always a self-limiting complication?
247. Plasma exchange for heparin-induced thrombocytopenia: is there enough evidence?
248. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC).
249. Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
250. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.
251. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy.
252. Heparin-induced thrombocytopenia.
253. Heparin-induced thrombocytopenia (HIT) as an unusual cause of acute stent thrombosis.
254. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.
255. HIV associated thrombocytopenia, misdiagnosed as thrombotic thrombocytopenic purpura: a case report.
256. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.
257. Immune thrombocytopenia in pregnancy.
258. Thrombopoietin and platelet production in chronic immune thrombocytopenia.
259. eComment: Heparin-induced thrombocytopenia.
260. Severe Thrombocytopenia in the NICU.
261. [Transitional cell carcinoma of the bladder metastatic to bone marrow presenting as isolated anaemia and thrombocytopenia].
262. International consensus report on the investigation and management of primary immune thrombocytopenia.
263. The mouse mutation "thrombocytopenia and cardiomyopathy" (trac) disrupts Abcg5: a spontaneous single gene model for human hereditary phytosterolemia/sitosterolemia.
264. Prospective, observational study of outcomes in neonates with severe thrombocytopenia.
265. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia.
266. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report.
267. Megakaryocytic alterations in thrombocytopenia: a bone marrow aspiration study.
268. Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid.
269. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia.
270. Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery.
271. [Massive haemothorax associated with essential thrombocytopenia after a minor thoracic trauma].
272. [Bivalirudine in heparin-induced thrombocytopenia].
273. Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia.
274. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases.
275. Heparin-induced thrombocytopenia: overview and treatment.
276. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
277. Innate immune cells induce hemorrhage in tumors during thrombocytopenia.
278. Antinuclear antibody (ANA)-positive thrombocytopenia: primary, but with a difference.
279. Efalizumab-induced severe thrombocytopenia can be resolved.
280. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.
281. Lepirudin in the management of patients with heparin-induced thrombocytopenia.
282. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.
283. Robot-assisted laparoscopic prostatectomy performed in a patient with severe thrombocytopenia due to primary myelofibrosis.
284. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
285. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.
286. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
287. Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
288. A patient with a leg rash, pedal edema, renal failure, and thrombocytopenia.
289. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
290. Regional anesthesia and non-preeclamptic thrombocytopenia: time to re-think the safe platelet count.
291. A pulmonary embolism caused by delayed-onset heparin-induced thrombocytopenia in a patient with ischemic stroke.
292. In vivo inactivation of MASTL kinase results in thrombocytopenia.
293. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia).
294. Do childhood vaccines cause thrombocytopenia?
295. Adverse prognostic significance of thrombocytopenia in acute coronary syndrome: can anything be done about it?
296. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.
297. [Neutropenia and/or thrombocytopenia due to acute parvovirus B19 infection].
298. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
299. Referral of patients with thrombocytopenia from primary care clinicians to hematologists.
300. Molecular mimicry and immune thrombocytopenia.
301. [Arthralgia, bone pain, positive antinuclear antibodies and thrombocytopenia...diagnosis: Niemann-Pick disease].
302. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.
303. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.
304. Pathobiology of secondary immune thrombocytopenia.
305. eComment: Plasmapheresis for near-fatal heparin-induced thrombocytopenia.
306. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature.
307. Thrombocytopenia in early alcohol withdrawal is associated with development of delirium tremens or seizures.
308. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection.
309. Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia.
310. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia.
311. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.
312. Significant correlation between spleen volume and thrombocytopenia in liver transplant patients: a concept for predicting persistent thrombocytopenia.
313. New insights into the mechanisms of nonimmune thrombocytopenia in neonates.
314. [Foetal/neonatal alloimmune thrombocytopenia. A review and case report].
315. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia.
316. Studies of the immune response in heparin-induced thrombocytopenia.
317. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells.
318. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
319. Cerebral infarction associated with heparin-induced thrombocytopenia in a patient with encephalitis.
320. eComment: Freedom Solo stentless aortic bioprosthesis and postoperative thrombocytopenia--interpretation of available data and clinical consequences for surgeons.
321. Acute profound abciximab induced thrombocytopenia: a correct management of a methodological error.
322. Pathobiology and treatment of hepatitis virus-related thrombocytopenia.
323. Anticoagulation in a Neurosurgical Patient with Heparin-Induced Thrombocytopenia Type II with Argatroban and Fondaparinux after Clipping of an Intracranial Aneurysm.
324. Redo aortic valve replacement after partial upper sternotomy (hemisternotomy) in a patient with idiopathic thrombocytopenia: a case report.
325. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.
326. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
327. Immune thrombocytopenia (ITP): an historical perspective.
328. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
329. An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance.
330. Fatal thrombocytopenia after oxaliplatin-based chemotherapy.
331. Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors.
332. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.
333. Chronic Plasmodium vivax infection in a patient with splenomegaly and severe thrombocytopenia.
334. Shunt operations improved thrombocytopenia in a patient with congenital cyanotic heart disease.
335. Thrombocytopenia in preterm infants with intrauterine growth restriction.
336. [Heparin-induced thrombocytopenia].
337. The role of platelet and plasma markers of antioxidant status and oxidative stress in thrombocytopenia among patients with vivax malaria.
338. Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia.
339. [Thrombocytopenia associated with brucellosis: a case report].
340. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.
341. Severe thrombocytopenia before liver transplantation is associated with delayed recovery of thrombocytopenia regardless of donor type.
342. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
343. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia.
344. Heparin-induced thrombocytopenia: a historical perspective.
345. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
346. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.
347. Case report: vancomycin-induced thrombocytopenia in a burn patient.
348. [Severe thrombocytopenia in a child with type 1 diabetes].
349. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
350. Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia.
351. Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/- mice.
352. Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis.
353. [Management of heparin-induced thrombocytopenia in a patient on hemodialysis complicated with thrombosis in the extracorporeal circuit].
354. [Thrombocytopenia in a patient on peritoneal dialysis].
355. Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.
356. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
357. Images in cardiovascular medicine. Acute reversible bioprosthetic mitral valve stenosis caused by heparin-induced thrombocytopenia.
358. Successful laparoscopic splenectomy after living-donor liver transplantation for thrombocytopenia caused by antiviral therapy.
359. Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia.
360. Urgent cardiac surgery in a patient with a remote history of heparin-induced thrombocytopenia: use of the anti-PF4/heparin ELISA confirmatory test.
361. HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia.
362. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
363. Human herpesvirus type 8 in patients with cirrhosis: correlation with sex, alcoholism, hepatitis B virus, disease severity, and thrombocytopenia.
364. Heparin-induced thrombocytopenia during renal replacement therapy in the intensive care unit.
365. Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series.
366. Safety of linezolid in patients with baseline thrombocytopenia.
367. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes.
368. Successful treatment of autoimmune pancreatitis complicated with autoimmune thrombocytopenia and interstitial pneumonia by prednisolone.
369. Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498).
370. Neonatal alloimmune thrombocytopenia.
371. Thrombocytopenia after aortic valve replacement with the Freedom Solo stentless bioprosthesis.
372. The financial impact of heparin-induced thrombocytopenia.
373. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q.
374. Severe thrombocytopenia associated with acute hepatitis E virus infection.
375. A 69-year-old woman with respiratory failure and thrombocytopenia.
376. Thrombocytopenia and mortality in infective endocarditis.
377. Mesalazine-induced jaundice, eosonophilia, and thrombocytopenia.
378. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.
379. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice.
380. Intraoperative anticoagulation management during cardiac transplantation for a patient with heparin-induced thrombocytopenia and a left ventricular assist device.
381. Reticulated platelets as a screening test to identify thrombocytopenia aetiology.
382. [Congenital amegakaryocytic thrombocytopenia in a 12 year old boy with no signs of pancytopenia: molecular analysis].
383. The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.
384. [Recurrent pulmonary embolism in a patient with heparin-induced thrombocytopenia].
385. Heparin-induced thrombocytopenia in a patient with lung embolism and left-sided pneumonia: a case report.
386. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy.
387. [Heparin immune thrombocytopenia in a hemodialysis patient. A case report. Literature review].
388. Eltrombopag in thrombocytopenia.
389. [Factors associated with thrombocytopenia among pregnant women in Cameroon].
390. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.
391. Improvement of thrombocytopenia in a patient with autoimmune pancreatitis after Helicobacter pylori eradication.
392. Inflammation induces hemorrhage in thrombocytopenia.
393. Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia.
394. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia.
395. [Persistent thrombocytopenia in a child: morphological examination of blood platelets established the diagnosis of Wiskott-Aldrich syndrome].
396. Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia.
397. How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity.
398. Platelet-induced clumping of Plasmodium falciparum-infected erythrocytes from Malawian patients with cerebral malaria-possible modulation in vivo by thrombocytopenia.
399. Thrombelastography in a patient with heparin-induced thrombocytopenia treated with argatroban.
400. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.
401. Rapid diagnosis of vivax malaria by the SD Bioline Malaria Antigen test when thrombocytopenia is present.
402. [Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.].
403. [A splenectomy in plasma exchange refractory thrombotic thrombocytopenia purpura.].
404. [Clinical usefulness of the simple technique to diagnose thrombocytopenia using immature platelet fraction].
405. Age as a risk factor for thrombocytopenia and anaemia in children treated for acute uncomplicated falciparum malaria.
406. [Platelet indices in chronic alcoholic liver disease patients with thrombocytopenia].
407. Heparin induced thrombocytopenia diagnosis in cardiac surgery: is there a role for thromboelastography?
408. [Nosocomial Candida infections and thrombocytopenia in very low birth weight newborns].
409. [Severe levofloxacin-induced thrombocytopenia].
410. Immune mediated neutropenia and thrombocytopenia in 3 giant schnauzers.
411. [Anesthesia for treatment of cardiac aspergillosis in a patient with thrombocytopenia and the judicious use of aprotinin.].
412. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
413. Delayed-onset heparin-induced thrombocytopenia presenting with multiple arteriovenous thromboses: case report.
414. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia.
415. Drug-induced immune thrombocytopenia.
416. HIV infection increases the risk of heparin-induced thrombocytopenia.
417. A case of heparin-induced thrombocytopenia with repeated episodes of acute lower extremity arterial thromboembolism during a short time.
418. [Heparin-induced thrombocytopenia].
419. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not?
420. Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.
421. Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia" rather than "X-linked gray platelet syndrome".
422. Impact of array comparative genomic hybridization-derived information on genetic counseling demonstrated by prenatal diagnosis of the TAR (thrombocytopenia-absent-radius) syndrome-associated microdeletion 1q21.1.
423. Neonatal alloimmune thrombocytopenia, purpura, and anemia in 6 neonatal piglets.
424. Heparin induced thrombocytopenia: diagnosis and management update.
425. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.
426. Heparin induced thrombocytopenia type II complicating coronary artery bypass surgery: a tale of caution.
427. Profound drug-induced thrombocytopenia before urgent cardiopulmonary bypass.
428. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.
429. Drug-induced thrombocytopenia.
430. A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus.
431. Thrombocytopenia as a prognostic factor in Hispanic patients with systemic lupus erythematosus: comment on the article by Fernández et al.
432. A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case outcome.
433. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
434. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria.
435. Clinico-pathological observations on the pathogenesis of severe thrombocytopenia and anemia induced by Plasmodium vivax infections during antimalarial drug efficacy trials in Aotus monkeys.
436. Urothelial carcinoma of the bladder metastatic to bone marrow presenting as isolated thrombocytopenia.
437. The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension.
438. Thrombocytopenia in leptospirosis and role of platelet transfusion.
439. Heparin-induced thrombocytopenia associated with fondaparinux.
440. [Budd-Chiari syndrome and severe thrombocytopenia in a patient with Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome].
441. Vancomycin-induced immune thrombocytopenia.
442. Sulfasalazine-induced immune thrombocytopenia.
443. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor.
444. Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report.
445. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia.
446. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (Rh(0)-D) immune globulin.
447. Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen.
448. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital.
449. Hepatitis C virus-associated thrombocytopenia is not related to serum thrombopoietin levels.
450. Long-term application of lepirudin on chronic haemodialysis over 34 months after heparin-induced thrombocytopenia.
451. Massive fetal hemorrhage and fetomaternal alloimmune thrombocytopenia from human platelet antigen 5b incompatibility: an unusual association.
452. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
453. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.
454. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population.
455. [Severe thrombocytopenia and human immunodeficiency virus infection. Report of two cases and review].
456. The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
457. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.
458. Vancomycin-induced immune thrombocytopenia.
459. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia.
460. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia.
461. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia.
462. Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation.
463. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor.
464. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome.
465. [Heparin-induced thrombocytopenia in hemodialysis. Case report and review of the literature].
466. Heparin-induced thrombocytopenia in a case of endovascular aneurysm coiling.
467. Platelet transfusion in neonatal alloimmune thrombocytopenia.
468. Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse.
469. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
470. Heparin-induced thrombocytopenia.
471. Persistent thrombocytopenia after Dengue hemorrhagic fever.
472. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
473. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.
474. Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma.
475. Acute eosinophilic pneumonia accompanied by mediastinal lymphadenopathy and thrombocytopenia.
476. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
477. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study.
478. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
479. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.
480. Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene.
481. Hemorrhage after auricular acupuncture due to postoperative dilutional thrombocytopenia.
482. [Polymorphic ventricular tachycardia in acute myocardial infarction without ST elevation in a patient with thrombocytopenia].
483. Thrombocytopenia in Plasmodium vivax infected children.
484. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
485. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
486. Thrombocytopenia in falciparum malaria is associated with high concentrations of IL-10.
487. A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.
488. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
489. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate.
490. Borderline thrombocytopenia or mild idiopathic thrombocytopenic purpura?
491. Heparin-induced thrombocytopenia.
492. Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report.
493. Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia.
494. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy.
495. Progressive nodular histiocytoma associated with thrombocytopenia with absent radii (TAR syndrome) and angiofibromas.
496. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies.
497. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.
498. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia.
499. A case of suspected lymphocytic hypophysitis and organizing pneumonia during maintenance therapy for autoimmune pancreatitis associated with autoimmune thrombocytopenia.
500. [Intracraneal hemorrhage caused by neonatal alloimmune thrombocytopenia. Report of a case and review].
501. The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT II)--dosage monitoring.
502. TNFalpha blocker-induced thrombocytopenia.
503. Oxaliplatin-induced immune thrombocytopenia.
504. Suspects in the tale of lupus-associated thrombocytopenia.
505. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
506. Thrombotic end point for assessing argatroban therapy for heparin-induced thrombocytopenia: learning from secondary analyses of prospective studies.
507. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia.
508. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient.
509. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.
510. A 77-year-old farmer with respiratory failure and thrombocytopenia.
511. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
512. Transient thrombocytopenia after incompatible red blood transfusion in an infant girl with autoimmune hemolytic anemia.
513. Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report.
514. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure.
515. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.
516. Editor's quiz: GI snapshot. Cholestatic hepatitis with marked thrombocytopenia.
517. Antigenic complementarity in the origins of autoimmunity: a general theory illustrated with a case study of idiopathic thrombocytopenia purpura.
518. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
519. Multifocal lymphangioendotheliomatosis with thrombocytopenia: a rare cause of gastrointestinal bleeding in the newborn period.
520. [Complications associated to severe thrombocytopenia in patients with dengue].
521. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
522. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
523. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C.
524. Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
525. Treatment of heparin-induced thrombocytopenia with drotrecogin alfa (activated).
526. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
527. Thrombopoietin in postoperative thrombocytopenia following living donor hepatectomy.
528. Heparin-induced thrombocytopenia: a complication of thromboprophylaxis.
529. Acute thrombocytopenia associated with preexisting ulcerative colitis successfully treated with colectomy.
530. Images in cardiovascular medicine. Multiple thrombosis with aortic occlusion after heparin-induced thrombocytopenia demonstrated by multislice computed tomography.
531. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
532. Pro: Should aspirin be continued after cardiac surgery in the setting of thrombocytopenia?
533. Bilateral renal artery thrombosis due to heparin-induced thrombocytopenia-thrombosis syndrome. Successful treatment with longterm application of lepirudin.
534. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit.
535. Thrombocytopenia in the experimental leptospirosis of guinea pig is not related to disseminated intravascular coagulation.
536. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus.
537. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT).
538. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia.
539. A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia.
540. Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia.
541. Intraoperative heparin and heparin-induced thrombocytopenia.
542. [Thrombocytopenia: clinicobiologic validation and classification].
543. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
544. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy.
545. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
546. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
547. Cell- rather than antibody-mediated immunity leads to the development of profound thrombocytopenia during experimental Plasmodium berghei malaria.
548. What is the appropriate anticoagulation therapy in patients with a history of heparin-induced thrombocytopenia?
549. Acute multifocal bacterial nephritis complicated with acute renal failure and thrombocytopenia.
550. Rituximab-induced acute thrombocytopenia: a report of two cases.
551. Delayed diagnosis of HIV-associated thrombocytopenia in a man of 70.
552. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
553. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.
554. Heparin-induced thrombocytopenia: an update.
555. Disseminated Nocardia farcinica infection in a uraemia patient with idiopathic thrombocytopenia purpura receiving steroid therapy.
556. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.
557. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
558. Increased nuchal translucency thickness in thrombocytopenia-absent-radius syndrome.
559. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo.
560. Thrombocytopenia and Plasmodium vivax malaria.
561. [Platelet associated immunoglobulin in the pathogenesis of thrombocytopenia in patients with chronic liver disease].
562. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia.
563. A case of neutropenia and thrombocytopenia shortly after initiaing olanzapine.
564. Lupus thrombocytopenia: clinical implications and prognostic significance.
565. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
566. Determination of thrombopoietin-derived peptides recognized by both cellular and humoral immunities in healthy donors and patients with thrombocytopenia.
567. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.
568. Acupuncture for acute postoperative pain relief in a patient with pregnancy-induced thrombocytopenia--a case report.
569. Sjögren's syndrome associated with chronic hepatitis C, severe thrombocytopenia, hypertrophic cardiomyopathy, and diabetes mellitus.
570. Immune-mediated thrombocytopenia in a 4-month-old German shepherd dog.
571. Lymphocyte apoptosis and thrombocytopenia in spleen during classical swine fever: role of macrophages and cytokines.
572. Thrombocytopenia associated with intravenous ciprofloxacin.
573. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.
574. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
575. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.
576. Bidirectional glenn shunt surgery using lepirudin anticoagulation in an infant with heparin-induced thrombocytopenia with thrombosis.
577. Genetic deletion of murine SPRY domain-containing SOCS box protein 2 (SSB-2) results in very mild thrombocytopenia.
578. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia.
579. Occurrence of thrombocytopenia in Plasmodium vivax malaria.
580. When heparins promote thrombosis: review of heparin-induced thrombocytopenia.
581. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study.
582. Heparin-induced thrombocytopenia: principles for early recognition and management.
583. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar.
584. The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia.
585. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.
586. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
587. Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient.
588. Thrombocytopenia in brucellosis: case report and literature review.
589. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
590. Thrombocytopenia in cardiovascular patients: diagnosis and management.
591. New approaches to the diagnosis of heparin-induced thrombocytopenia.
592. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia.
593. Cases of heparin-induced thrombocytopenia elucidate the syndrome.
594. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment.
595. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.
596. Thrombocytopenia following MMR vaccination.
597. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia.
598. Syndrome of inappropriate secretion of antidiuretic hormone and thrombocytopenia caused by cytomegalovirus infection in a young immunocompetent woman.
599. Caspofungin: a potential cause of reversible severe thrombocytopenia.
600. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.